MedTrace Logo

A Comparison of Morphine and Morphine Plus Dexmedetomidine in Chronic Cancer Pain

NCT02289261 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2018-06-19

No results posted yet for this study

Summary

The purpose of this study is to determine whether dexmedetomidine added to morphine is effective in the treatment of chronic cancer pain.

Conditions

Interventions

DRUG

Morphine

Morphine, 0.02 mg/kg PCA bolus dose with 10 minutes lock-out interval

DRUG

Morphine plus dexmedetomidine

Morphine 0.02 mg/kg plus dexmedetomidine 0.1 microgram/kg PCA bolus dose with 10 minutes lock-out interval

Sponsors & Collaborators

  • Cukurova University

    lead OTHER

Principal Investigators

  • Selcuk Gök, M.D · Cukurova University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-11-30
Primary Completion
2015-02-28
Completion
2015-02-28

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02289261 on ClinicalTrials.gov